CNE000000ZW7
CNE000000ZW7
TIBET RHODIOLA PHARMACEUTICAL H
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 11.85B EUR | 12.05B EUR | 13.08B EUR | 13.71B EUR |
Enterprise Value | 9.45B EUR | 10.2B EUR | 11.31B EUR | 12.19B EUR |
Valuation Multiples | ||||
Trailing P/E | 12.02x | 14.62x | 16.09x | 17.5x |
Forward P/E | 8.84x | -- | -- | -- |
Price to Sales | 4.11x | 4.93x | 5.12x | 5.39x |
Price to Book | 2.99x | 3.08x | 3.35x | 3.61x |
EV/Revenue | 3.28x | 4.17x | 4.43x | 4.79x |
EV/EBITDA | 10.69x | 11.22x | 12.45x | 13.83x |
Price to FCF (P/FCF) | 29.07x | 15.88x | 13.73x | 15.63x |
EV/FCF | 23.17x | 13.45x | 11.87x | 13.89x |
FCF Yield | 3.44% | 6.3% | 7.28% | 6.4% |